Conquering Diseases

Study Of An Investigational Drug For Advanced Relapsed, Refractory, Or Resistant Hematological (Blood) Cancer

Description

Seeking men and women with advanced relapsed, refractory, or resistant hematological (blood) cancer with an IDH mutation that has not responded or stopped responding to prior treatment for participation in a study of an investigational drug.

Overview

Participants in this study will receive the investigational drug as a tablet taken by mouth. Frequent study visits taking up to 3 hours are required while the best dose is being assessed. After the second 28-day cycle the study visits are only on the 1st day of the cycle.

What we're hoping for

We are studying what is the maximum safe dose of an investigational drug and whether it is safe and effective for advanced relapsed, refractory, or resistant hematological cancer with an IDH mutation.

Additional Information

ClinicalTrials.gov Identifier: NCT04764474

 Principal Investigator

Jonathan M. Gerber, MD

University of Massachusetts Medical School

 Study Contact

The Cancer  Research Office

508-856-3216

Cancer.research@umassmed.edu

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989